Ascendis Pharma initiates clinical trial of dwarfism drug

Danish biotech company Ascendis Pharma’s achondroplasia treatment, Transcon CNP, will be clinically tested across six sites in China.

Photo: Kevin Grønnemann

Ascendis Pharma has initiated a hunt for new patients for a phase II trial in China, according to the Clinical Trials database.

The study is looking for around 64 patients aged 2 to 10 years to evaluate the safety and tolerability of drug candidate Transcon CNP as a treatment for achondroplasia, also known as dwarfism.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs